[Action of calcium dobesilate on capillary fragility in diabetics].
Calcium dobesylate was administered for 30 days to diabetics with or without clinical signs referable to microangiopathy and increased capillary fragility unaccompanied by coagulation and haemostasis disturbances. Good results were observed in 90% of cases. It is felt that the drug can also be used in the tertiary prevention of systemic microangiopathy, as well as the medical management of diabetic retinopathy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002123:Calcium Dobesilate / Q000627:therapeutic use*; D002198:Capillary Fragility / Q000187:drug effects*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D001557:Benzenesulfonates; D002123:Calcium Dobesilate
Azione del dobesilato di calcio sulla fragilità capillare del diabetico.